What is the primary indication for Labetalol as stated by the FDA?

Labetalol is primarily indicated for the treatment of hypertension (HTN) as per FDA guidelines. It is a combined alpha and beta-adrenergic blocker, which helps lower blood pressure by reducing heart rate and the force of the heart's contraction, as well as by dilating blood vessels. This dual-action mechanism makes labetalol particularly effective for managing high blood pressure, especially in situations where rapid control is necessary, such as in hypertensive emergencies or during pregnancy.

The other conditions listed are not the primary indications for labetalol. While labetalol may be used in certain circumstances for congestive heart failure or in specific cases of heart failure management, those uses are secondary compared to its established role in hypertension treatment. Cerebrovascular accident is a type of emergency condition that may require treatment with various agents, but labetalol is not specifically indicated for the management of stroke. Heart failure with preserved ejection fraction also does not align with the primary use of labetalol, as management typically involves other therapeutic classes. Therefore, the focus on hypertension aligns with labetalol’s primary and most well-supported FDA indication.